Aurora A is critical for survival in HPV-transformed cervical cancer

Brian Gabrielli¹,⁶,⁷ Fawzi Bokhari¹,⁷, Max V. Ranall¹, Zay Yar Oo¹, Alexander J Stevenson¹, Weili Wang¹, Melanie Murrell², Mushfiq Shaikh², Sora Fallaha², Daniel Clarke², Madison Kelly², Karin Sedelies³, Melinda Christensen⁵, Sara McKee¹, Graham Leggatt¹, Paul Leo¹, Dubravka Skalamera¹, H. Peter Soyer⁴, Thomas J Gonda¹,⁵ and Nigel AJ McMillan²,⁶

¹The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia; ²Griffith Health Institute, School of Medical Science, Griffith University, Gold Coast, Australia; ³Mater Research, The University of Queensland, Translational Research Institute, Brisbane, Australia. ⁴Dermatology Research Centre, School of Medicine, The University of Queensland, Translational Research Institute, Brisbane, Australia.

⁵Current Address; School of Pharmacy, The University of Queensland, Brisbane Australia.

⁶Corresponding authors

⁷These authors contributed equally to this work

Running Title: Aurora A inhibitor targets cervical cancer

Conflict of Interest: The authors have no conflicts of interest to declare.

Financial Support: This work was supported by grants from the National Health and Medical Research Council (NHMRC) Australia (B.Gabrielli and N.McMillan), Australian Cancer Research Fund (T.Gonda), Cancer Council Queensland (N.McMillan), Worldwide Cancer
Research (formerly Association for International Cancer Research) (B.Gabrielli) and The University of Queensland Diamantina Institute. F.Bokhari was supported by a scholarship from The Medical Service Division, Ministry of Defence, Saudi Arabia. B.Gabrielli is an NHMRC Senior Research Fellow.

Corresponding Authors:

Professor Brian Gabrielli
The University of Queensland Diamantina Institute
Translational Research Institute,
Brisbane, QLD. Australia 4102
Email: brianG@uq.edu.au

Professor Nigel McMillan
Director, Molecular Basis of Disease Program, Menzies Health Institute Queensland
Griffith University, Gold Coast Campus,
Southport 4222 QLD
Australia
Email: n.mcmillan@griffith.edu.au

Notes:

Word Count; 4800
6 Figures
0 Tables
Abstract

Human papillomavirus (HPV) is the causative agent in cervical cancer. HPV oncogenes are major drivers of the transformed phenotype, and the cancers remain addicted to these oncogenes. A screen of the human kinome has identified inhibition of Aurora kinase A (AURKA) as being synthetically lethal on the background of HPV E7 expression. The investigational AURKA inhibitor MLN8237/Alisertib selectively promoted apoptosis in the HPV cancers. The apoptosis was driven by an extended mitotic delay in the Alisertib-treated HPV E7 expressing cells. This had the effect of reducing Mcl-1 levels which is destabilised in mitosis, and increasing BIM levels, normally destabilised by Aurora A in mitosis. Over-expression of Mcl-1 reduced sensitivity to the drug. The level of HPV E7 expression influenced the extent of Alisertib-induced mitotic delay and Mcl-1 reduction. Xenograft experiments with three cervical cancer cell lines showed Alisertib inhibited growth of HPV and non-HPV xenografts during treatment. Growth of non-HPV tumours was delayed, but in two separate HPV cancer cell lines, regression with no resumption of growth was detected, even at 50 days post-treatment. A transgenic model of premalignant disease driven solely by HPV E7 also demonstrated sensitivity to drug treatment. Here we show for the first time that targeting of the Aurora A kinase in mice using drugs such as Alisertib results in a curative sterilising therapy may be useful in treating HPV-driven cancers.
Introduction

Human papillomavirus (HPV) has been identified as the definitive agent in cancers of the cervix, penis, vulva, vagina, anus, skin, eye, and head and neck, and is responsible for over 610,000 deaths, 5% of the total cancer burden worldwide (1). The papillomaviruses are small, double-stranded DNA viruses belonging to the family Papillomaviridae. High-risk HPVs have been identified as the causative agent in 99.7% cervical cancers (2), have been detected in more than 50% of other anogenital cancers, and in over 70% of cancers of the oropharynx (3, 4). The most prevalent high-risk HPV types are HPV-16 and HPV-18, which account for ~70% of HPV-cancer cases, with another 10 high-risk types making up the other 30% (5).

While HPV vaccines are available and highly effective (reviewed in (6)), they are clearly most useful if given before viral exposure. Even with the advent of vaccines, cervical cancer will remain a serious health issue in unvaccinated and under-vaccinated women (7). The use of more targeted approaches is now beginning to improve outcomes in other cancers but no such therapy for HPV-driven cancers is in the clinic. Indeed, chemo-radiotherapy is still the primary treatment modality and there has been little improvement in 5-year outcomes (8).

High risk HPV promotes cancer via the actions of the E6 and E7 oncogenes. The E6 gene product binds to the p53 tumor suppressor protein and targets it for ubiquitin-mediated degradation (9). E6 also blocks senescence by stimulating telomerase activity as well as an increasing number of other proteins range (10). The E7 protein also has a range of targets including the retinoblastoma protein (pRB) family, the MuvB complex, and directly drives genomic instability (10, 11). Therefore, the over-expression of E6 and E7 allows uncontrolled cell growth and increased genomic instability, which promotes transformation and carcinogenesis. This process occurs over an extended timeframe (up to 20 years) due to
the fact that E6/E7 alone are not sufficient to drive cancer; secondary mutational events also contribute (12) thus making specific treatment difficult as each HPV cancer has a different spectrum of mutations.

The one consistent feature of cervical cancers is the continued dependence on HPV E6 and E7 expression. Depletion of E6/E7 is sufficient to drive even long established cell lines into either senescence or apoptosis, depending on the level of depletion achieved (13). This continuing dependence on E6/E7 suggests that drugs that targeting E6/E7 are also likely to be selective for HPV-transformed cancers. We have undertaken a functional genomics screen to identify genes involved in E6/E7-driven dependency that are essential to the survival of HPV-driven cancers. Here we show for the first time that targeting of the Aurora A kinase using the inhibitor Alisertib results in a profound inhibition of HPV-driven tumor growth, and that this selectivity is through targeting an interaction between Aurora A and HPV E7 in mitosis.
Materials and Methods

Cell culture

All cervical cancer cell lines were originally obtained from the American Type Culture Collection (ATCC) except for the C33A. Cervical cancer cell lines (HeLa, CaSki, ME-180, SiHa, C33A, HT3, and C33A-HPV16-E7) were maintained in complete Dulbecco’s Modified Eagle Medium (DMEM) (GIBCO, Invitrogen, Mulgrave, Victoria, Australia) supplemented with 10% serum supreme (Biowhittaker, Lonza, Mt Waverley, Victoria, Australia), 1mM sodium pyruvate (GIBCO) and 2mM L-glutamine (GIBCO) at 37°C and 5% CO₂. Squamous cell carcinoma cell lines were kindly given by Associate Professor Nicholas Saunders (The University of Queensland Diamantina Institute, Brisbane, Australia) and were cultured in DMEM/F12 (1:1) (GIBCO) containing 10% serum supreme (Lonza) at 37°C and 5% CO₂. All cell lines were tested and free of mycoplasma and authenticated with STR fingerprinting at the time of use. SCC25 cells were transduced with lentivirus expressing HPV18 E7 or empty vector as described previously (14). The vector places the HPV18 E7 5’ of an IRES GFP resulting in GFP co-expression at a level which is an indicator of the level of E7 expression. qPCR analysis of relative E7 gene expression using delta-delta CT analysis and β-actin as the housekeeper.

siRNA screening

Detailed methods for the siRNA screening are provided in the Supplementary Material.

Flow cytometry

All tested cells were exposed to final concentrations of 5µM Alisertib, 5µM ZM447439, or DMSO (vehicle) for 24, 48, or 72 hours. Cells were analysed for DNA content by flow
Cytometry using BD FACS-Canto II (BD Biosciences, San Jose, CA) and data analysed with FlowJo software (FlowJo Co., Ashland, OR) as described previously (15).

**Time-lapse microscopy**

Cells were either treated with 5µM Alisertib or DMSO (vehicle), then followed by time-lapse microscopy using a Zeiss Axiovert 200M Cell Observer microscope equipped with an incubation chamber at 37°C and 5% CO2. Images were captured at 20 minute intervals with a minimum of 150 cells per condition per cell line analysed as described previously (15). Time in mitosis and exit from mitosis was observed and assessed for successful cellular division, failure of cytokinesis, or cell death.

**Immunoblotting**

Cells were lysed and immunoblotted as described previously using chemiluminescence detection imaged with a CCD camera (15). Band intensities were quantitated using ImageJ software. Antibodies to Bim, Bcl-2, PARP, cleaved Caspase 3 (Cell Signalling), Aurora A and Aurora B (Becton-Dickinson), Bcl-XL (AbCam), Mcl-1 (Millipore) and α-tubulin (Sigma Aldrich) were purchased from the indicated suppliers.

**Mouse xenograft models**

Mice (6-weeks old female Nude, ARC, Perth, Australia) were inoculated subcutaneously in the right flank with 1x10⁶ cells in Matrigel. For each cell line, 6 mice were used for the treatment with Alisertib and 6 for the vehicle control only. When tumors were palpable (~1 week following injection) 100 µl oral gavage of 30 mg/kg Alisertib was administered daily for 10 consecutive days. Mice were then scored daily by scoring any tumor regrowth or until culled. All animal studies were approved by University of Queensland Animal Ethics.
K14E7 transgenic mouse grafting experiments

Groups of seven mice, with well healed (up to 5 months) grafts of either wild type or K14E7 skin were treated with or without two cycles of Alisertib as for the xenograft experiments. At between 2 and 10 days after the final cycle, mice were sacrificed and grafts harvested for immunohistochemical staining. Formalin fixed, paraffin embedded samples were either immunostained for cleaved caspase 3 (Cell Signaling) or mast cells using toluidine blue, pH 1. The number of cells stained was visually assessed by microscopy.

Immunofluorescence

Cells were cultured on poly-L-lysine coated glass coverslips in with vehicle (DMSO) or 5 µM Alisertib for 24- or 48-hours. Coverslips were fixed with -20°C methanol and stored at -20°C until processing. Coverslips were stained for microtubules and DNA as described previously (16).

qPCR

Extract of RNA, cDNA generation and qPCR were carried out as described previously described (17).
Results

SiRNA library screen and target selection

In order to discover synthetic lethal interactions with the HPV oncogenes E7 and E6 in cervical cancers, we undertook an siRNA library kinome screen using the Dharmacon human siGENOME siRNA library for Protein Kinases (targeting 779 genes). The primary screen used CaSki (cervical cancer HPV16), and C33A (cervical cancer non-HPV) cell lines. Data were normalised using z-score transformation for each assay and cell line, and genes sorted by z-score on CaSki viability. Using the parameters of viability, cytotoxicity and cell number we identified genes that when depleted were selectively lethal to the HPV-positive CaSki cell line compared the HPV-negative C33A cells (Figure 1A; full screening data presented in Supplementary Table S1). This was visualised using hierarchical clustering and Principle Components Analysis (details of the analysis are provided in Supplementary Figure S1). We identified a group of genes whose knockdown resulted in reduced viability in all cells, including PLK1, WEE1, and COPB2, which were excluded from further analysis. From this primary screen we identified a set of 54 genes for secondary screening using the OnTarget Plus siRNA Smart Pools which have reduced off-target effects due to their modified passenger strand and >90% have different target sites (Supplementary Table S2). The secondary screen siRNAs were applied to a larger panel of cell lines including HeLa (HPV18), SiHa (HPV16) and HaCaT (HPV-negative) cells using the viability, cytotoxicity and cell count assay parameters.

From the secondary screen we identified the genes AURKA and AURKB as the strongest hits (those with the highest z scores) in all three assays (Figure1B; Figure S2). Other genes such as GSG2, SYK, MAPK12, PRKAR2B and STK22C showed activity in one or two assays, but not in all three. Using Western analysis, we confirmed siRNA depletion of the respective target proteins of our two top hits, Aurora A and Aurora B kinases. Moreover,
we observed no obvious differential expression of these proteins in HPV and non-HPV cancer lines (Figure 1C). With three of the top seven targets (AURKA, AURKB and GSG2) acting as regulators of mitosis it suggested that mitosis may be the common target in the HPV cancers. However, two mitotic inhibitors, the Plk1 inhibitor, BI-2536 and paclitaxel showed no selectivity between the HPV-positive and -negative cell lines (Supplementary Figure S3), suggesting a more specific mechanism may be responsible for the HPV-mediated sensitivity.

HPV-cancer cell lines are highly sensitive to inhibition of Aurora A Kinase in vitro and in vivo

To validate the Aurora kinases as selective targets in HPV-driven cervical cancer, we assessed the activity of well-characterised inhibitors of Aurora A and B. The Aurora B inhibitor ZM447439 (18) was not selective for the HPV lines (Supplementary Figure S4). The potent, orally active inhibitor of Aurora A kinase, MLN8237/Alisertib (19) was investigated in a panel of HPV-transformed cervical cancer cell lines. HeLa, CaSki and ME180 (HPV18/38) were highly sensitive to Alisertib with IC50 values of less than 1µM, while SiHa were less sensitive with an IC50 of 1.2 µM (Figure 2A; Table S3). The non-HPV cervical cancer cell line HT3 and C33A was less sensitive with an IC50 of 2 and 16 µM, respectively (Figure 2B; Table S3). We also tested a panel of squamous cell carcinoma (SCC) cell lines to increase the number of non-HPV cancer cell lines from a keratinocyte origin. These were significantly less sensitive to Alisertib with IC50 values above 5µM in all cases (Figure 2C). The difference in drug sensitivity was not a consequence of different proliferative rates, as all cell lines tested had a similar doubling time. The sensitivity of the HPV-cervical cancer cell lines are clinically relevant as plasma concentrations of 1-5µM of Alisertib have been reported in patients (20).

To assess the ability of Alisertib to inhibit tumor growth in vivo, nude mice were
injected subcutaneously with either HeLa (HPV16), CaSki (HPV18), or C33A (non-HPV) lines. When tumors had formed and were palpable, Alisertib treatment (orally, 30 mg/kg daily for 10 days) was initiated. The non-HPV C33A tumors showed an initial inhibition of growth that continued to 10 days after the final treatment, but tumor growth recovered to control levels thereafter. By contrast, HeLa and CaSki tumors reached approximately 20-35 mm³ during the treatment phase then regressed with Alisertib treatment, with no signs of tumor at day 50 post-treatment (Figure 3A), and excision of the original site of inoculation showed no residual tumor.

We also assessed a transgenic model of HPV16 E7 dependent pre-cancer using a skin graft model. In this model, donor mice have HPV16 E7 expression controlled by the keratin 14 promoter (K14E7) resulting in E7 expression in squamous epithelial keratinocytes, driving hyperplasia of the keratinocytes (21). Grafting of skin from either wild type or K14E7 mice onto a syngeneic host results in well healed grafts (22). Mice with well-healed grafts underwent two cycles of 10-day Alisertib treatment, and the mice where then sacrificed and the grafts harvested for immunohistochemical analysis. This treatment resulted in swelling and reddening of the K14E7 grafts only. In Alisertib-treated E7 grafts we observed a significant increase in apoptotic cells compared to untreated E7 grafts (Figure 3B). No apoptotic cells were detected in the adjacent wild type grafts. There was also an increase the number of mast cells immediately adjacent to the epidermis in the Alisertib treated E7 grafts compared to both the adjacent wild type grafts and untreated E7 grafts (Figure 3C; Supplementary Figure S5), likely to be in part responsible for the increased swelling of the Alisertib-treated E7 grafts.

Treatment with Alisertib induces polyploidy and cell death in HPV-transformed cervical cancer cell lines.
Cell cycle progression was analysed in cells after Alisertib treatment by flow cytometry. Treatment of cells with 5 μM Alisertib for 24 h resulted in increased cells with 4N and >4N DNA and a reduction in the 2N and S phase population in all cell lines (Figure 4A; Figure S6, S7A). There was an increase in the sub-diploid population (<2N) in a time-dependent manner in all cell lines, which was more pronounced in HPV-transformed cells. After 72 h of treatment, 3 of the 4 HPV-transformed showed high sub-diploid population (HeLa, 70%; Caski and ME180, 75%) indicating cell death. The exception was SiHa, where the sub-diploid population was 36%. By contrast, the two non-HPV cancer cell lines, C33A and HT3, demonstrated lower sub-diploid populations of 14%, and 31%, respectively, but accumulated cells with high polyploidy (>4N) suggesting that a failed cytokinesis but this did not result in cell death.

To confirm that the induction of 4N and >4N DNA content was a consequence of failure of cytokinesis, all cell lines were subject to immunofluorescence staining of the microtubule cytoskeleton with anti-α-tubulin and DAPI for DNA (Figure S7B). The percentage of binuclear and multinuclear cells 1 and 2 days post-Alisertib treatment increased to a similar level in all cells (Figure S7C). Together, this data suggest that the accumulation of cells with 4N or greater DNA content was indeed a consequence of failure of cytokinesis but only in HPV-transformed cells did this result in a significant loss of viability.

The effects of Alisertib on cell viability were confirmed using time-lapse microscopy. In all cell lines, drug treatment caused cells to arrest in mitosis (rounded mitotic morphology), and undergo failed cytokinesis (producing single daughter cells). However, apoptosis was prominent in the HPV-transformed cell lines (Figure S8). Analysis of the timing of cell death in the HPV-transformed cell lines showed that 50-60% of cells underwent two rounds of mitosis before triggering cell death quickly, while a further 20% required a single mitosis, but then death was delayed for >20h (Figure S9). Surprisingly, the
length of mitotic arrest induced by the drug was up to 5 times longer in the HPV-transformed lines (Figure 4A). Aurora A inhibition normally results in a relatively short mitotic delay then exit into failed cytokinesis (23-25). Our data suggests a unique sensitivity in cells where HPV is present that results in a highly extended mitotic arrest.

Mechanism of Alisertib-induced death in HPV cancer cell lines

To examine the apoptosis induced by Alisertib treatment, HeLa cells overexpressing either Bcl-2 or Mcl-1 were assessed for their sensitivity to Alisertib. Etoposide and taxol were used as respective positive controls. The Mcl-1-HeLa cells were highly resistant to Alisertib compared to the parental HeLa, with a >50-fold increase in IC$_{50}$ (90nM to 4.7 μM). Interestingly, Bcl-2 over-expression had a more modest effect on sensitivity to Alisertib (Figure 5A). Mcl-1 and Bcl-2 over-expression were protective against taxol and etoposide, respectively (Figure S10), suggesting Alisertib functions via an Mcl-1-sensitive apoptotic mechanism.

A panel of apoptotic components was examined by immunoblotting of the HPV-transformed cervical cancer cell lines after 24, 48, and 72 h of Alisertib treatment. The level of full-length poly-ADP ribose polymerase (PARP) decreased with a concomitant increase in cleaved PARP in all HPV cell lines tested by 48 h drug treatment. This was not detected in the non-HPV C33A line (Figure 5B; Figure S11). The increased PARP cleavage was associated with an increase in the cleavage and activation of Caspase 3. The levels of the anti-apoptotic Mcl-1, Bcl-2, and Bcl-Xl proteins varied between each cell line. Alisertib treatment had little effect on the levels of Bcl-2 and Bcl-Xl, but there was up to 50% reduction in the level of Mcl-1 in three of the HPV-transformed lines. Alisertib treatment had little effect on either the relatively insensitive SiHa or the non-HPV C33A line. Tumor suppressor p53 was only readily detectible by immunoblotting in the non-HPV cell lines and
was not restored in the HPV-transformed lines by Alisertib treatment. The expression of p53-regulated pro-apoptotic proteins PUMA, NOXA and BAD, were not affected by Alisertib treatment. An increase in the level of the Mcl-1 selective BIM in the majority of cell lines treated was observed (Figure 5B, C). The consistently reduced level of Mcl-1 in the Alisertib-treated HPV-transformed cell lines together with the increased level of BIM and the resistance to Alisertib of HeLa cells over-expressing Mcl-1 indicates that the reduced Mcl-1 and increased BIM levels are the mechanism by which apoptosis is induced by Alisertib treatment.

**Aurora A inhibition targets host interaction with HPV E7**

In order to determine if Alisertib-sensitivity was a direct consequence of expression of HPV oncogenes, C33A non-HPV cervical cancer and SCC25 non-HPV SCC cell lines were transfected with HPV16 E7 oncogene, then assessed for their sensitivity to Alisertib. Expression of E7 in SCC25 cells (SCC25-HPV16-E7) resulted in >30 fold reduction of the IC\textsubscript{50} (from >15 to 0.5 μM) while E7 expression in C33A cells (C33A-HPV16-E7) resulted in ~50% IC\textsubscript{50} reduction (Figure 6A and Figure S12), indicating E7-expression induces the observed sensitivity. Our previous experiments hint that the level HPV E7 expression appeared to be correlated with sensitivity to Alisertib as the lowest E7-expressing line, SiHa, (26) was the least sensitive (Figure 2). To assess whether the level of HPV E7 expression influences Alisertib sensitivity, SCC25 lines were transduced with lentivirus HPV18 E7 as an IRES GPF labelled expression construct. The resultant population was FACS sorted into low and high GFP expression as a direct marker of HPV E7 expression (14) (Figure S13). These populations where treated with 5 μM Aliserib, and the delay in mitosis and changes in apoptotic proteins assessed as before. We observed a dose-dependent increase in mitotic delay between the low and high expressing cells upon Alisertib treatment (Figure 6B), which
was highly significant (p<0.005) in the E7-high expressing population. Increased BIM levels were observe in all Alisertib treated population, but a reduced Mcl-1 level (to 50% control) was only observed in E7-high expressing population at 3 days, correlated with decreased full length PARP (Figure 6C). These data together indicate that the expression of HPV E7 is responsible for the increased sensitivity of the HPV-transformed cell lines, and that the level of HPV E7 expression is an important determinant of sensitivity to Alisertib.
Discussion

Here we have used siRNA kinome screening to identify Aurora A as a molecular target for killing HPV-driven cervical cancer cells. Previously, shRNA-based kinome screens from the Harlow and Munger laboratories have explored the role of E7 synthetic lethality but only 100 kinases were screened and these did not include any of our seven top hits (27).

The Aurora A inhibitor, Alisertib, has been used in over 35 clinical trials, however, it has so far only elicited modest responses in range of tumor settings (20, 28, 29). Targeting Aurora A using Alisertib demonstrated selectivity for HPV-transformed cancer cells both in vitro and in vivo. In vitro, the major difference observed was that the HPV cell lines failed cytokinesis and died whereas non-HPV cervical cancer lines failed cytokinesis but remained viable. In xenograft experiments, we observed that non-HPV cervical cancer was somewhat sensitive to Alisertib treatment, showing delayed tumor growth and eventual recovery, a typical response reported for Alisertib in other cancer models (30, 31). By contrast no tumor was detectible in either HeLa or CaSki cells, even 50 days post-treatment. Although Alisertib had a more modest effect in mouse K14E7 grafted model, the lack of effect on the adjacent wild-type graft demonstrates the same selectivity observed in the cancer models. The increased apoptosis and mast cell infiltrate point to Alisertib treatment having an HPV-E7 directed effect even in this pre-malignant setting. Together, these data provide strong evidence that Aurora A selectively targets HPV E7 expressing cells in vitro and in vivo.

This observation is supported by the mechanistic studies, which shows Aurora A depletion/inhibition selectively kills HPV-transformed cervical cancer cell and this is dependent on HPV E7 expression. The expression HPV E7 in HPV-negative C33A and SCC25 sensitised them to Alisertib and the level of E7 correlated with sensitivity. HPV E7 expression has been reported to increase Aurora A levels (32), though we found little difference in the level of Aurora A in HPV and non-HPV cancer cell lines. HPV E7 can up-
regulate the expression of the p53-related p73 protein via dysregulated E2F activity, which can transactivate the expression of the pro-apoptotic proteins PUMA and NOXA. Aurora A has been reported to phosphorylate p73, and HPV E7 regulated gene (33), and inhibit its transcriptional activity, thus inhibiting the expression of p73 regulated PUMA and NOXA promoting apoptosis (25, 34). However, we found no evidence of this mechanism in Alisertib-dependent death in the HPV-transformed cancer cell lines.

A consistent difference between the Alisertib-treated HPV-transformed and non-HPV cell lines is the time in mitosis, with the HPV-transformed lines all delaying up to five time longer in mitosis as non-HPV cells. This data and the finding that a majority of cells required transit through one or two mitoses before undergoing apoptosis suggested that the extended mitotic delay was a major contributor to the selective killing observed. A number of components of the apoptotic pathway have been reported to be regulated by mitosis. Mcl-1 is destabilised by CDK1-Cyclin B (35, 36), and BIM, an Mcl-1 selective BH3-only protein (37), is phosphorylated by Aurora A which promotes its degradation in mitosis. Our data indicate that the apoptosis promoted by Alisertib treatment in the HPV-transformed cells is dependent on Mcl-1. The mechanism by which Aurora A regulates Mcl-1 stability is linked to the increased delay in mitosis found with Aurora A inhibition in the HPV-transformed cells. The longer delay in mitosis increases the destruction of Mcl-1. In addition to this reduction in anti-apoptotic signal, inhibition of Aurora A directly stabilises BIM, increasing pro-apoptotic signalling. Others have shown that BIM depletion reduced the sensitivity of HeLa cells to Aurora A inhibitor (38), supporting the role for BIM in this apoptotic signalling. The combined effect of reduced Mcl-1 and maintenance of BIM levels, which bound by Mcl-1, results in elevated BIM not bound in an anti-apoptotic Mcl-1 complex. The degree of Mcl-1 destruction during the mitotic delay may be the factor determining whether one or two mitoses are required for triggering apoptosis, as observed in the time lapse
experiments. CDK1-Cyclin B phosphorylation of BCL-2 and Bcl-Xl has also been reported to inhibit their anti-apoptotic activity (39), and the combined effect of reduction of anti-apoptotic Bl-2, Bcl-Xl and Mcl-1, with maintenance of BIM levels promoting an overall pro-apoptotic signal.

It may be that the level of E7 expression directly influences CDC20 expression and thereby Mcl-1 stability in mitosis. The level of HPV E7 expression contributes to length of the mitotic delay in Alisertib-treated cells. Low level E7 expression had little effect on time of E7 transduced SCC25 cells in mitosis with Alisertib treatment, but high level expression in these cells delayed significantly extended the mitotic delay. Only the high level HPV E7 expressing SCC25 cells showed significant reduction in Mcl-1 levels, consistent with this proposal. The mechanism underlying the effect of Aurora A inhibition in the E7 expressing cells is at present unknown. In summary, we have identified inhibition of Aurora A as a synthetic lethal target in the presence of the HPV E7 oncogene and demonstrated that inhibiting Aurora A with the small-molecule inhibitor Alisertib selectively and effectively targets HPV E7 expressing cells in vivo. The data presented here demonstrate that targeting Aurora A with drugs such as Alisertib may be an effective therapy for recurrent cervical cancer, and may be useful in treating other HPV-transformed cancer types.
Acknowledgements

The authors thank Takeda Pharmaceuticals for the Alisertib, A/Prof Nigel Waterhouse and Prof David Huang for their gifts of Mcl-1 expression vector and the Mcl-1 expressing HeLa cells, and Dr Fiona McMillan and Prof Ian Frazer for their critical reading of the manuscript.
References


10. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to


Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aura


Figure Legends

Figure 1. Kinome siRNA screen of cervical cancer cells.

A. Cell viability (resazurin) analysis following treatment of CaSki and C33A cells with the Dhharmacon Human siGENOME SMARTpool siRNA Library. Each data point represents a mean Z-score of three replicates. B. Summary of the top 54 selected hits from the primary screen rescreened using OnTarget Plus siRNA in an expanded panel of cell lines. Only the cytotoxicity data are shown. The top two hits from this validation set are indicated (box). C Cells transfected with either Aurora A kinase (AURKA) or Aurora B kinase (AURKB) ON-Target Plus siRNA and harvested 24 h after transfection. Non-targeting siRNA (siNT) was used as a control. The levels of Aurora A or Aurora B were assayed for the appropriate siRNA, with α-tubulin as a loading control.

Figure 2. HPV-transformed cancer cell lines are more sensitive to Alisertib than non HPV cancer cells.

Dose response curves and IC50 values generated for Alisertib on a panel of HPV (A), non-HPV (B) and SCC (C) cancer cell lines using cell viability (resazurin) as the readout. The IC50 values calculated from four replicates are shown.

Figure 3. Alisertib selectively targets HPV E7-expressing cells in two mouse models.

A. Groups of six mice were injected with either CaSki (HPV16), HeLa (HPV18), or C33A (non-HPV) cervical cancer cells subcutaneously in one flank of each mouse. In each group, mice were treated with 30 mg/kg Alisertib or carrier for 10 consecutive days and then followed up daily until culled, with the control treated group culled when the tumor size reach 500-600 mm³. The bar indicates the time of treatment. B. Groups of seven mice, with well healed grafts of either wild type or K14E7 skin were treated with or without two 10-day
cycles of Alisertib as described for the xenograft experiments. Formalin fixed, paraffin embedded samples were immunostained for cleaved caspase 3. The number of cells stained was scored visually by microscopy. The number of cells in ten 20X fields from each mouse are shown. C. Skin sections from B were stained for mast cells, and the numbers of mast cells immediately adjacent to the epidermis were counted in five 20X fields. * indicates p>0.05.

Figure 4. Alisertib treatment of HPV-transformed cancer cells promotes apoptosis and delays HPV-transformed cells in mitosis.

A. HPV-transformed cancer cells were treated with 5 μM Alisertib and sampled at intervals over 72 h and analysed by flow cytometry for DNA content. The data are the mean and standard deviation of three independent experiments. The data for only CaSki and C33A are shown. See Figure S6A and S12 for other cell lines. ME180 and C33A cell line data is shown in Supplementary Figure S4. B. Quantitation of the time in mitosis for each cell line with and without 5 μM Alisertib treatment determined from the time-lapse experiments. The data are the mean and 95% confidence interval for > 100 cells in each case.

Figure 5. Mcl-1 over expression reduced the sensitivity to Alisertib.

A. Dose response of parental, Bcl-2 and Mcl-1 over expressing HeLa cells to Alisertib. The IC50 values for each from four determinations are shown. B. The indicated cell lines were treated with 5 μM Alisertib for up to 3 days. Cells were lysed and immunoblotted for the indicated apoptotic proteins. These data are representative of three independent experiments. C. Quantitation of the Mcl-1 and BIM levels from at least three independent experiments similar to that shown in B. The levels are normalised to the day 0 control for each cell line. * indicates p>0.05, ** p>0.01 compared to control.
Figure 6. Expression of HPV E7 is sufficient to sensitize cells to Alisertib.

A. IC50 values for the parental and HPV16 E7 expressing C33A and SCC25 cell lines determined from four replicate experiments. Example curves used to derive the combined data are shown in Figure S13. B. Quantitation of the time in mitosis for each SCC25 cell lines transduced with different levels of HPV E7 with and without 5 mM Alisertib treatment determined from time-lapse experiments. The data are the mean and 95% confidence interval for >100 cells in each case. *** indicates a p<0.005 compared with the empty vector control using one way ANOVA. C. SCC25 cell lines were transduced with different levels of HPV E7 were treated with 5 mM Alisertib for up to 3 days. Cells were lysed and immunoblotted for the indicated apoptotic proteins. D. The level of HPV E7 transcript expression is shown relative to CaSki.
Figure 1

A

B

C

HeLa CaSki SiHa C33A HaCaT

NT si NT si NT si NT si NT si

Z-Score Cytotoxicity

| Gene      | ACVRL1 | ADRB2 | ANGPT4 | AURKA | AURKB | AURKC | BCR | BMPR2 | CAMK1D | CASK | CKS1B | CNKSR1 | CSNK1D | DAPK1 | DCK | DGKE | DUSP10 | EGFR | EPHA2 | FLJ10074 | GRK4 | GSG2 | HUNK | IRAK3 | KSR2 | MAGI-3 | MAP2K6 | MAP3K2 | MAP3K7 | MAPK10 | MAPK12 | MARK3 | MERTK | MINK | MYLK2 | NEK7 | NEK8 | PDIK1L | PIK3CA | PIK3R3 | PKIA | PRKAR2B | PRKCN | PRPSAP2 | PTPRJ | RAGE | RPS6KA3 | SSTK | STK16 | STK22C | SYK | TEX14 | TGFBR1 | NT #1 | PLK1 |
|-----------|--------|-------|--------|-------|-------|-------|-----|-------|--------|------|-------|--------|--------|-------|-----|------|-------|------|-------|-----------|------|------|-------|-------|-------|--------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
Figure 2

A

IC50 (µM)
- HeLa 0.04 ± 0.01
- SiHa 2.9 ± 0.1
- ME180 0.09 ± 0.03
- CaSki 0.70 ± 0.34
- C33A 16 ± 1.9
- HT3 2.1 ± 1.3

B

IC50 (µM)
- C33A 16 ± 1.9
- HT3 2.1 ± 1.3

C

IC50 (µM)
- Colo 21.5 ± 1.6
- FaDu 8.8 ± 1.2
- Detroit 5.7 ± 1.2
- SCC25 >20
- KJD >20

% Control
0 25 50 75 100 125

[Alisertib] µM
0 0.1 1 10 100
Figure 3

A

C33A

CaSki

HeLa

Tumour Volume (mm3)

Days treatment

Control

Alisertib

B

apoptotic cells

E7

E7+

Alisertib

C

Mast cells

E7

Wt+

E7+

Alisertib
Figure 4

A

CaSki (HPV+ve)

% population

Time after Drug addition (h)

<2N

2N

S

4N

>4N

C33A (HPV-ve)

B

HPV+ve

HPV-ve

HeLa  ME180  CaSki  SiHa  C33A  HT3

Time in mitosis (min)

Control  +Alisertib
Figure 5

A

IC50 (µM)

- HeLa 0.09 ± 0.02
- HeLa-Mcl-1 4.7 ± 0.8
- HeLa-Bcl-2 0.25 ± 0.02

[Alisertib] µM

% Control

B

CaSki HeLa C33A

PARP

Bcl-2

Bcl-XL

Mcl-1

Cleaved Casp3

α-tub

days Alisertib

C

Mcl-1

% Control

CaSki HeLa SiHa ME180 C33A

Bim

% Control

CaSki HeLa SiHa ME180 C33A
Figure 6

A

IC50 (µM)

<table>
<thead>
<tr>
<th></th>
<th>C33A</th>
<th>C33A E7</th>
<th>SCC25</th>
<th>SCC25 E7</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>14.7</td>
<td>6.5</td>
<td>0.5</td>
<td></td>
</tr>
</tbody>
</table>

B

Time in mitosis (min)

Empty | E7 lo | E7 hi | Alisertib

C

Relative gene expression

D